Last reviewed: June 28, 2026

Last updated: June 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy is indeed a pen—specifically, a pre-filled injection device containing semaglutide, a GLP-1 receptor agonist approved by the FDA for chronic weight management in adults. The medication activates brain receptors that regulate appetite and blood sugar, helping patients achieve an average weight loss of 15–22% over 68 weeks in clinical trials. PlexusDx offers compounded semaglutide injections from licensed 503A pharmacies as a personalized alternative, with treatment starting at $149 per month and available in all 50 states without insurance.

How Wegovy Pens Deliver Semaglutide for Weight Loss

Wegovy's pen design holds a liquid solution of semaglutide that patients inject subcutaneously once weekly into the abdomen, thigh, or upper arm. The needle is small and thin, designed for minimal discomfort during self-administration. Each pen is color-coded by dose strength, making it easy to identify your prescribed level. The pre-filled mechanism eliminates the need to draw medication from a vial, reducing preparation time and potential dosing errors.

Semaglutide works by mimicking glucagon-like peptide-1 (GLP-1), a hormone that signals fullness to the brain's appetite centers. This dual action reduces hunger intensity and increases feelings of satiety, allowing patients to eat less without constant willpower battles. The medication also slows gastric emptying—the rate at which food leaves your stomach—prolonging the sensation of being full between meals. Clinical data shows that patients on semaglutide consume approximately 500 fewer calories daily compared to placebo groups.

Clinical Evidence: Real-World Weight Loss Results with Semaglutide

The STEP trials, a series of phase 3 clinical studies involving over 4,500 adults, demonstrated semaglutide's effectiveness for weight reduction. Participants receiving the 2.4 mg dose achieved an average weight loss of 15.3 kg (approximately 34 pounds) over 68 weeks, compared to just 2.6 kg in the placebo group. This represents a 9.8% average body weight reduction—a clinically meaningful outcome for reducing obesity-related conditions including type 2 diabetes and heart disease risk.

Beyond weight loss, semaglutide improved cardiovascular health markers in trial participants. Blood pressure, LDL cholesterol, and inflammation markers all showed measurable improvement. Patients also reported better metabolic function and improved glucose control, even those without a diabetes diagnosis. These benefits often persist as long as patients continue treatment, making semaglutide a long-term weight management solution rather than a temporary intervention.

Compounded Semaglutide vs. Brand-Name Wegovy: Key Differences

While Wegovy is the brand-name, FDA-approved version, PlexusDx offers compounded semaglutide prepared by licensed 503A pharmacies—a distinct regulatory category that ensures pharmaceutical-grade quality standards. Compounded medications are made to order based on individual prescriptions, allowing personalization of strength and format. The active ingredient is identical to Wegovy's semaglutide, but compounded versions may be offered at lower monthly costs without requiring insurance or membership fees.

PlexusDx's compounded semaglutide injection starts at $149 per month and is available across all 50 states. Patients can pay with HSA or FSA funds, providing tax-advantaged flexibility for managing healthcare expenses. The treatment approach remains medically equivalent—once-weekly injections with the same mechanism of action—yet offers accessibility for those seeking personalized dosing without the brand-name premium. Your dose may need to go up as your body responds to treatment; your price remains fixed at your tier commitment.

Understanding Your Genetic Response to Semaglutide Treatment

Not all patients respond identically to semaglutide, and genetic factors play a significant role in treatment outcomes. Your GLP-1 receptor gene (GLP1R rs6923761), GIPR rs1800437 variant, and FTO rs9939609 marker all influence how effectively your body uses this medication. PlexusDx's Precision Peptide Genetic Test maps 14 pathways and 49 peptides across 150+ genetic insights, helping your provider predict your individual response pattern before treatment begins.

The genetic test costs $99 as an add-on after your first month of treatment, allowing PlexusDx to create a truly personalized protocol tailored to your molecular biology. Patients with certain genetic variants may respond more robustly to semaglutide, while others might benefit from different GLP-1 options or combination therapies like GLP-Squared (semaglutide plus tirzepatide). This precision approach removes guesswork and optimizes your likelihood of sustained weight loss success.

Managing Side Effects and Building Tolerance to Semaglutide

The most frequently reported side effects of semaglutide include nausea, vomiting, constipation, and diarrhea—typically mild to moderate and occurring most during dose escalation phases. These effects usually diminish within 1–2 weeks as your body adjusts to the medication. Taking semaglutide with food, staying hydrated, and eating slowly can significantly reduce nausea risk. Most patients find that gastrointestinal symptoms become negligible once they reach their maintenance dose.

Serious adverse events are rare but include pancreatitis, gallbladder issues, and allergic reactions. Patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 should avoid semaglutide entirely. Your PlexusDx provider will review your complete medical history and current medications before prescribing to ensure safety. If you experience severe abdominal pain, persistent vomiting, or signs of allergic reaction, contact your healthcare provider immediately.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is Wegovy the only brand of semaglutide available for weight loss?

No. While Wegovy is the brand-name version, compounded semaglutide from licensed 503A pharmacies offers an equivalent medication at a lower cost. PlexusDx provides compounded semaglutide injections starting at $149 per month without requiring insurance, making it accessible to more patients seeking GLP-1 therapy for weight management.

How much weight can I expect to lose with a semaglutide pen?

Clinical trials show average weight loss of 15–22% body weight over 68 weeks with semaglutide therapy. Individual results vary based on genetics, lifestyle factors, and adherence to treatment. PlexusDx's Precision Peptide Genetic Test can help predict your personal response likelihood using analysis of your GLP-1 and appetite-regulation genes.

Can I afford semaglutide without insurance coverage?

Yes. PlexusDx's compounded semaglutide injection costs $149 per month flat across all dose levels—no insurance required, no membership fee. You can also use HSA or FSA funds to cover the cost, providing additional tax-advantaged savings on your weight loss treatment.

What makes compounded semaglutide safer than other options?

PlexusDx sources all semaglutide from licensed 503A compounding pharmacies, which adhere to strict FDA guidelines for pharmaceutical quality and sterility. Compounded medications are individually prepared to prescription, allowing dose customization and reducing waste. The active ingredient is identical to brand-name Wegovy; only the formulation and delivery mechanism may differ slightly.

Will the Precision Peptide Genetic Test tell me if semaglutide will work for me?

The test ($99 add-on after month one) analyzes genetic variants in GLP-1R, GIPR, FTO, and MC4R—genes directly involved in appetite regulation and metabolic response to GLP-1 therapy. While it doesn't guarantee outcomes, it predicts your likely response pattern and can guide your provider toward the most effective protocol, whether that's semaglutide, tirzepatide, or a dual-compound approach.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves